Thursday, April 23, 2009

Sandoz gets Canadian nod to market Omnitrope

Sandoz Canada has received market authorization for Omnitrope in Canada. Omnitrope is the first version of a previously approved recombinant biotechnology drug to be approved by Health Canada under the regulatory term Subsequent Entry Biologic (SEB).

the details can be read here.

No comments: